share_log

NETRAMARK ANNOUNCES SHARES FOR DEBT SETTLEMENT

PR Newswire ·  Jul 6, 2023 06:36

TORONTO, July 5, 2023 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) announces that it has entered into debt settlement agreements with certain consultants, pursuant to which the Company has agreed to settle an aggregate amount of $240,000 in outstanding debt in exchange for the issuance of 600,000 common shares in the capital of the Company (the "Common Shares") at a deemed price of $0.40 per share (the "Debt Settlement"). Pursuant to the policies of the Canadian Securities Exchange, the Debt Settlement cannot close prior to five business days from the date of this announcement.

The Common Shares issued in connection with the Debt Settlement will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.

About NetraMark

NetraMark is a company focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI / ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and / or efficacy of treatment.

For further details on the Company please see the Company's publicly available documents filed on the System for Electronic Document Analysis and Retrieval (SEDAR).

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment